



Standard Classification for Tissue Engineered Medical Products (TEMPs)¹

This standard is issued under the fixed designation F2211; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This classification outlines the aspects of tissue engineered medical products that will be developed as standards. This classification excludes traditional transplantation of organs and tissues as well as transplantation of living cells alone as cellular therapies.

1.2 This classification does not apply to any medical products of human origin regulated by the U.S. Food and Drug Administration under 21 CFR Parts 16 and 1270 and 21 CFR Parts 207, 807, and 1271.

1.3 This standard does not purport to address specific components covered in other standards. Any safety areas associated with the medical product's use will not be addressed in this standard. *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory requirements prior to use.*

2. Referenced Documents

2.1 ASTM Standards:²

F2027 Guide for Characterization and Testing of Raw or Starting Biomaterials for Tissue-Engineered Medical Products

F2064 Guide for Characterization and Testing of Alginates as Starting Materials Intended for Use in Biomedical and Tissue Engineered Medical Product Applications

F2103 Guide for Characterization and Testing of Chitosan Salts as Starting Materials Intended for Use in Biomedical and Tissue-Engineered Medical Product Applications

F2131 Test Method for *In Vitro* Biological Activity of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Using the W-20 Mouse Stromal Cell Line

¹ This classification is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.41 on Classification and Terminology for TEMPs.

Current edition approved Oct. 1, 2013. Published December 2013. Originally approved in 2002. Last previous edition approved in 2004 as F2211 – 04, which was withdrawn in January 2013 and reinstated in October 2013. DOI: 10.1520/F2211-13.

² For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

F2150 Guide for Characterization and Testing of Biomaterial Scaffolds Used in Tissue-Engineered Medical Products

2.2 Federal Documents:³

US FDA CFR 21, Part 3 [3.2(e)] Product Jurisdiction

21 CFR Parts 16 and 1270 Human Tissues, Intended for Transplantation

21 CFR Parts 207, 807, and 1271 Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing

2.3 ISO Standard:

ISO 10993 Biological Evaluation of Medical Devices⁴

3. Terminology

3.1 *tissue engineering, n*—the application, *in vivo* and *in vitro*, of scientific principles and technologies to form tissue engineered medical products (TEMPs) used for medical treatments and as diagnostics. The various technologies and principles are common practices and methods in engineering and biomedical sciences such as cell, gene, or drug therapy, embryology or other forms of developmental biology, surgical methods and technologies used to create traditional devices and biologics. Tissue engineering could be applied to create products for non-human use as well.

3.2 *tissue engineered medical products (TEMPs), n*—medical products that repair, modify, or regenerate the recipients' cells, tissues, and organs, or their structure and function, or combination thereof. TEMPs may achieve a therapeutic potential from cells, biomolecules, scaffolds, and other materials, and processed tissues and derivatives used in various combinations or alone. TEMPs are unique from conventional organ transplants. TEMPs may be used *in vivo* or *in vitro* for disease, injury, elective surgery, and as a diagnostic.

3.3 For other definitions used in this classification, refer to the terms developed by the subcommittee on tissue engineered medical products terminology.

3.3.1 *Discussion*—ASTM Committee F04 is continuing to refine definitions for tissue engineered medical products

³ Available from U.S. Government Printing Office Superintendent of Documents, 732 N. Capitol St., NW, Mail Stop: SDE, Washington, DC 20401.

⁴ Available from International Organization for Standardization (ISO), 1 rue de Varembe, Case postale 56, CH-1211, Geneva 20, Switzerland.